 |
|
|
 |
Monoclonal antibody may control Crohn's disease in children
Crohn's disease, a painful inflammation of the gastrointestinal tract,
affects more than 100,000 children in the U.S., causing emotional and social
difficulties in addition to its physical symptoms. more
|
|
Risk for a biological weapons attack is increasing
Bioterrorism is one of the greatest threats to U.S. national security. Dr. Greg Evans, director of the Center for the Study of Bioterrorism and
Emerging Infections at Saint Louis University School of Public Health, is
available to discuss this threat. more
|
|
|
|
Structure of key breast cancer receptor determined
A team of scientists from Johns Hopkins and the biotechnology company
Genitope has unlocked the 3-D structure of a receptor that goes awry in 20
percent to 30 percent of breast cancers. Reporting in the Feb. 13 issue of
the journal Nature, the scientists also figured out how the receptor, known
as HER2, interacts with an antibody, sold as Herceptin, that is used to
treat thousands of breast cancer patients each year. more
|
|
Effexor XR approved for the treatment of social anxiety disorder
Wyeth announced today that the U.S. Food and Drug Administration (FDA)
approved Effexor® XR (venlafaxine HCl) for the treatment of patients
with social anxiety disorder (SAD), which may affect up to 13 percent of
Americans at some point in their lives. more
|
|
Prescribing information: Effexor® XR (Venlafaxine HCl)
Effexor® XR is a serotonin and norepinephrine reuptake inhibitor that
uses dual reuptake inhibition, meaning it increases the levels of both
serotonin and norepinephrine. By inhibiting both serotonin and
norepinephrine reuptake, it may be possible to help more patients achieve
remission.
more
|
|
|
